A C T I V A T I N G T H E P O W E R W I T H I N
Corporate Overview
N A S D A Q : V B I V | M a y 2 0 2 1 |
Forward-Looking Statements
Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively "forward-looking statements"). The company cautions that such statements involve risks and uncertainties that may materially affect the company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the impact of the recent COVID-19 outbreak on our clinical studies, manufacturing, business plan and the global economy; the ability to obtain appropriate or necessary governmental approvals to market potential products, including the approval of Sci-B-Vac® in the U.S., Europe, and Canada following the completion of its recent Phase 3 studies; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the company, is set forth in the Company's filings with the Securities and Exchange Commission and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2021, and filed with the Canadian security authorities at sedar.com on March 2, 2021, and may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
2
About VBI : Immune to Limitations
Through our innovative | ||||||||||||||||
We are a biotechnology | approach to virus-like | Our belief in the | ||||||||||||||
particles, our vision is to | ||||||||||||||||
company driven by | importance of protecting | |||||||||||||||
stimulate and amplify the | ||||||||||||||||
immunology in the pursuit | and enhancing human | |||||||||||||||
human immune system to | ||||||||||||||||
of powerful prevention and | life is at the core of | |||||||||||||||
target and overcome | ||||||||||||||||
treatment of disease | everything we do | |||||||||||||||
significant, aggressive, | ||||||||||||||||
and urgent infectious | ||||||||||||||||
diseases and cancers | ||||||||||||||||
3
The Science of Virus-Like Particles (VLPs)
Transforming natural immunity into potent protection and treatment
VLPs
Virus-Like Particles
Antigenic Protein | Lipid Bilayer |
eVLPs
Enveloped Virus-Like Particles
- VBI's Proprietary Platform Technology -
Sub-unit vaccines with no infectious material
VLPs mimic the natural presentation of viruses
Limited targets, however, as only a few antigens self-assemble into orderly VLP structures (incl. the Hepatitis B surface antigens)
No infectious
genetic
machinery
Gag Protein
eVLPs expand the list of potentially-viable target indications by providing a stable core (Gag Protein) and lipid bilayer
Flexible and customizable
Highly immunogenic with demonstrated safety profile
VBI's pipeline programs consist of both self-assembling | |
VLP candidates and eVLP candidates | 4 |
VBI's Pipeline : Both Sides of the Fight
VBI's broad spectrum of vaccine and immunotherapeutic candidates are designed to power the immune system to prevent and treat disease
Prophylactic Candidates | |||||||
Disease | Program | Technology | Preclinical | Phase 1 | Phase 2 | Phase 3 | Approved |
Hepatitis B (HBV) | 3-Antigen Vaccine Candidate | VLP | Approved in Israel | ||||
Cytomegalovirus (CMV) | VBI-1501 | eVLP | as Sci-B-Vac® | ||||
COVID-19 | VBI-2902 (monovalent) | eVLP | |||||
COVID-19 (B.1.351 Variant) | VBI-2905 (monovalent) | eVLP | |||||
Coronaviruses | VBI-2901 (multivalent) | eVLP | |||||
Coronaviruses | Undisclosed (multivalent) | eVLP | |||||
Zika | VBI-2501 | eVLP | |||||
Therapeutic Candidates | |||||||
Disease | Program | Technology | Preclinical | Phase 1 | Phase 2 | Phase 3 | Approved |
Hepatitis B (HBV) | VBI-2601(BRII-179) | VLP | |||||
Glioblastoma (GBM) | VBI-1901 | eVLP | |||||
Other CMV+ Tumors | Undisclosed | eVLP |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
VBI Vaccines Inc. published this content on 26 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 May 2021 20:48:05 UTC.